NASDAQ : SLXN
Silexion Therapeutics Corp — Financial statements
Healthcare · Biotechnology · Israel
Last price 0.1452 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 807.35K
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2013 | FY2012 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 5.01M | 4.49M | 6.76M | 973.00K | 236.00K | 166.00K |
| Research & Development | 9.11M | 7.14M | 5.82M | 3.71M | 1.12M | 787.00K |
| Operating Expenses | 14.13M | 11.63M | 12.57M | 4.68M | 1.36M | 953.00K |
| Operating Income | -14.13M | -11.63M | -12.57M | -4.68M | -1.36M | -953.00K |
| Interest Expense | -13.00K | -13.00K | -27.00K | -3.00K | -4.00K | |
| Interest & Investment Income | 167.00K | 155.00K | 28.00K | 153.00K | 4.00K | 6.00K |
| Currency Exchange Gain (Loss) | -139.00K | -127.00K | -247.00K | -453.00K | 2.00K | 13.00K |
| Other Non Operating Income (Expenses) | 154.00K | -292.00K | -3.69M | -95.00K | ||
| Pretax Income | -13.96M | -11.91M | -16.51M | -5.08M | -1.35M | -938.00K |
| Income Tax Expense | 3.00K | 10.00K | 32.00K | |||
| Earnings From Continuing Operations | -13.96M | -11.91M | -16.52M | -5.11M | -1.35M | -938.00K |
| Minority Interest in Earnings | 76.00K | 166.00K | ||||
| Net Income | -13.96M | -11.91M | -16.44M | -4.94M | -1.35M | -938.00K |
| Net Income to Common | -13.96M | -11.91M | -16.44M | -4.94M | -1.35M | -938.00K |
| Shares Outstanding (Basic) | 360.25K | 132.95K | ||||
| Shares Outstanding (Diluted) | 360.25K | 132.95K | ||||
| EPS (Basic) | -38.75 | -89.60 | ||||
| EPS (Diluted) | -38.75 | -89.60 | ||||
| Free Cash Flow | -12.43M | -10.83M | -8.42M | -4.54M | -799.00K | -914.00K |
| Free Cash Flow Per Share | -34.51 | -81.44 | ||||
| EBITDA | -14.12M | -11.62M | -12.55M | -4.64M | -1.35M | -951.00K |
| D&A For EBITDA | 12.00K | 14.00K | 25.00K | 45.00K | 3.00K | 2.00K |
| EBIT | -14.13M | -11.63M | -12.57M | -4.68M | -1.36M | -953.00K |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2013 | FY2012 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 2.23M | 5.99M | 1.19M | 4.59M | 788.00K | 1.60M |
| Cash & Short-Term Investments | 2.23M | 5.99M | 1.19M | 4.59M | 788.00K | 1.60M |
| Other Receivables | 89.00K | 161.00K | ||||
| Receivables | 89.00K | 161.00K | ||||
| Prepaid Expenses | 1.37M | 570.00K | 966.00K | 335.00K | 13.00K | |
| Restricted Cash | 29.00K | 27.00K | 35.00K | 25.00K | ||
| Other Current Assets | 111.00K | 49.00K | 62.00K | 24.00K | 38.00K | 29.00K |
| Total Current Assets | 3.74M | 6.64M | 2.25M | 4.98M | 928.00K | 1.79M |
| Property, Plant & Equipment | 368.00K | 437.00K | 560.00K | 247.00K | 9.00K | 7.00K |
| Other Long-Term Assets | 137.00K | 141.00K | 53.00K | 30.00K | ||
| Total Assets | 4.25M | 7.21M | 2.86M | 5.26M | 937.00K | 1.79M |
| Accounts Payable | 1.18M | 787.00K | 929.00K | 319.00K | 102.00K | 81.00K |
| Accrued Expenses | 1.56M | 1.74M | 1.38M | 1.56M | 139.00K | 87.00K |
| Short-Term Debt | 985.00K | 1.00M | ||||
| Current Portion of Leases | 199.00K | 182.00K | 158.00K | 112.00K | ||
| Current Income Taxes Payable | 51.00K | 51.00K | 47.00K | |||
| Other Current Liabilities | 2.00K | 200.00K | ||||
| Total Current Liabilities | 3.98M | 2.76M | 3.52M | 2.20M | 241.00K | 168.00K |
| Long-Term Debt | 1.57M | 2.96M | ||||
| Long-Term Leases | 226.00K | 286.00K | 368.00K | 59.00K | ||
| Total Liabilities | 4.20M | 4.61M | 6.85M | 2.25M | 241.00K | 168.00K |
| Common Stock | 160.00K | 42.00K | 2.00K | |||
| Additional Paid-In Capital | 61.33M | 57.73M | 39.26M | 11.34M | 5.16M | 4.74M |
| Retained Earnings | -61.45M | -55.17M | -43.25M | -26.81M | -4.47M | -3.11M |
| Total Common Equity | 44.00K | 2.60M | -3.99M | -15.48M | 696.00K | 1.63M |
| Minority Interest | 3.42M | |||||
| Shareholders' Equity | 44.00K | 2.60M | -3.99M | 3.00M | 696.00K | 1.63M |
| Total Liabilities & Equity | 4.25M | 7.21M | 2.86M | 5.26M | 937.00K | 1.79M |
| Total Debt | 1.41M | 2.04M | 4.49M | 171.00K | ||
| Net Cash (Debt) | 819.00K | 3.96M | -3.30M | 4.42M | 788.00K | 1.60M |
| Net Cash Per Share | 2.27 | 29.75 | ||||
| Filing Date Shares Outstanding | 5.56M | 333.08K | 56.10K | |||
| Total Common Shares Outstanding | 5.56M | 312.67K | 12.32K | |||
| Working Capital | -235.00K | 3.88M | -1.27M | 2.78M | 687.00K | 1.62M |
| Book Value Per Share | 0.01 | 8.33 | -323.65 | |||
| Tangible Book Value | 44.00K | 2.60M | -3.99M | -15.48M | 696.00K | 1.63M |
| Tangible Book Value Per Share | 0.01 | 8.33 | -323.65 | |||
| Machinery | 108.00K | 99.00K | 77.00K | 18.00K | 13.00K | |
| Leasehold Improvements | 56.00K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2013 | FY2012 | |
|---|---|---|---|---|---|---|
| Net Income | -13.96M | -11.91M | -16.44M | -4.94M | -1.35M | -938.00K |
| Depreciation & Amortization | 12.00K | 14.00K | 25.00K | 45.00K | 3.00K | 2.00K |
| Loss (Gain) From Sale of Assets | 16.00K | -1.00K | ||||
| Stock-Based Compensation | 618.00K | 134.00K | 5.86M | 130.00K | 424.00K | 40.00K |
| Other Operating Activities | -97.00K | 344.00K | 3.72M | 152.00K | ||
| Change in Accounts Receivable | 61.00K | -97.00K | ||||
| Change in Accounts Payable | 488.00K | -142.00K | 610.00K | 79.00K | 21.00K | 55.00K |
| Change in Other Net Operating Assets | 507.00K | 743.00K | -2.19M | 8.00K | 52.00K | 27.00K |
| Operating Cash Flow | -12.43M | -10.82M | -8.40M | -4.53M | -794.00K | -911.00K |
| Capital Expenditures | -2.00K | -9.00K | -22.00K | -12.00K | -5.00K | -3.00K |
| Sale of Property, Plant & Equipment | 78.00K | |||||
| Investment in Securities | 507.00K | |||||
| Other Investing Activities | -6.00K | -5.00K | -11.00K | -25.00K | ||
| Investing Cash Flow | -8.00K | -14.00K | -22.00K | 573.00K | -16.00K | -28.00K |
| Long-Term Debt Repaid | -696.00K | -250.00K | ||||
| Net Debt Issued (Repaid) | -696.00K | -250.00K | ||||
| Issuance of Common Stock | 12.61M | 18.68M | 3.05M | 1.72M | ||
| Other Financing Activities | -1.38M | -2.34M | 2.30M | |||
| Financing Cash Flow | 11.23M | 15.64M | 5.10M | 522.00K | 1.72M | |
| Foreign Exchange Rate Adjustments | -12.00K | -2.00K | -61.00K | -230.00K | ||
| Net Cash Flow | -1.22M | 4.80M | -3.38M | -3.66M | -810.00K | 782.00K |
| Free Cash Flow | -12.43M | -10.83M | -8.42M | -4.54M | -799.00K | -914.00K |
| Free Cash Flow Per Share | -34.51 | -81.44 | ||||
| Levered Free Cash Flow | -6.51M | -2.41M | -305.62K | |||
| Unlevered Free Cash Flow | -6.50M | -2.39M | -303.75K | |||
| Cash Interest Paid | 13.00K | 27.00K | ||||
| Change in Working Capital | 995.00K | 601.00K | -1.58M | 87.00K | 134.00K | -15.00K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2013 | FY2012 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 834.04K | 6.00M | 3.22M | 41.98M | ||
| Enterprise Value | 15.04K | -1.21M | 5.56M | 41.19M | ||
| Last Close Price | 0.15 | 19.20 | 301.50 | 14,647.49 | ||
| PB Ratio | 18.35 | 2.31 | -0.81 | 13.99 | ||
| P/TBV Ratio | 18.35 | 2.31 | ||||
| Debt / Equity Ratio | 32.05 | 0.78 | -1.13 | 0.06 | ||
| Net Debt / Equity Ratio | -18.61 | -1.52 | -0.83 | -1.47 | -1.13 | -0.98 |
| Net Debt / EBITDA Ratio | 0.06 | 0.34 | -0.26 | 0.95 | 0.58 | 1.68 |
| Net Debt / FCF Ratio | 0.07 | 0.36 | -0.39 | 0.97 | 0.99 | 1.75 |
| Quick Ratio | 0.56 | 2.17 | 0.34 | 2.09 | 3.64 | 10.47 |
| Current Ratio | 0.94 | 2.41 | 0.64 | 2.27 | 3.85 | 10.64 |
| Return on Equity (ROE) | -116.66% | |||||
| Return on Assets (ROA) | -144.28% | -193.54% | -62.13% | |||
| Return on Capital Employed (ROCE) | -5,232.20% | -261.00% | 1,904.70% | -153.00% | -195.10% | -58.60% |
| Earnings Yield | -25,830.43% | -198.43% | -510.32% | -11.77% | ||
| FCF Yield | -1,539.85% | -180.37% | -261.26% | -10.82% |